VIDEO: New tools help to individualize obesity, comorbidity treatment
Click Here to Manage Email Alerts
NEW ORLEANS — In the third part of this video exclusive, James R. Gavin III, MD, PhD, talks with Jamy D. Ard, MD, about new drugs for substantial weight loss and treatment of obesity-related comorbidities, including type 2 diabetes and liver disease.
Gavin is clinical professor of medicine at Emory University and chief medical officer of Healing Our Village. He is a Healio | Endocrine Today Co-Editor. Ard is professor of epidemiology and prevention and co-director of the Weight Management Center at the Wake Forest School of Medicine and an Endocrine Today Editorial Board Member.
“One of my main concerns as these new therapies come on the market is it will continue to be the ‘haves’ vs. the ‘have-nots,’” Ard said. “The ‘haves’ will continue to see the benefits of these newer therapies and the ‘have nots’ will basically have to wait until something comes off patent. ... That’s an unfortunate scenario ... we have to protect against.”
Collapse
Click Here to Manage Email Alerts